Pharvaris (PHVS) Corporate presentation summary

Scientific and clinical foundation

• Deucrictibant is an oral bradykinin B2 receptor antagonist with orphan drug designation in the U.S., Europe, and Switzerland, targeting bradykinin-mediated angioedema (AE-BK) including hereditary (HAE) and acquired forms (AAE-C1INH).

• The mechanism directly blocks the main mediator of swelling and inflammation, with potential to prevent or treat attacks regardless of bradykinin source.

• Two formulations—immediate-release (IR) capsule for rapid, on-demand treatment and extended-release (XR) tablet for once-daily prophylaxis—enable flexible patient management.

Clinical development and efficacy

• Three late-stage programs are ongoing: pivotal Phase 3 studies for both on-demand and prophylactic use in HAE, and a pivotal Phase 3 study in AAE-C1INH for label expansion.

• RAPIDE-3 data show rapid symptom relief (median 1.28 hours) and complete resolution (median 11.95 hours) for on-demand treatment.

• CHAPTER-1 and OLE studies demonstrate early, sustained attack prevention and placebo-like tolerability for prophylaxis, with up to 92.4% reduction in attacks.

• XR formulation maintains therapeutic exposure for over 24 hours, supporting once-daily dosing.

Market opportunity and patient needs

• The U.S. HAE market is projected to reach $4.7B by 2036, with significant growth in long-term prophylaxis and on-demand segments.

• Patients express strong preference for effective, well-tolerated, and convenient oral therapies, with up to 98% preferring oral LTP and high dissatisfaction with current options.

• Delays in treatment are common due to cumbersome administration of current therapies, leading to more severe and prolonged attacks.